FIELD: medicine, biology.
SUBSTANCE: invention relates to application of tissue factor agonist, namely FVII or FVIIa to induce or increase cell journey, as well as to application tissue factor antagonist modified with FVII to reduce or avoid cell journey in treatment of pathological conditions associated with specific control of cell journey or chemotaxis.
EFFECT: method for treatment of improved effectiveness.
14 cl, 14 ex, 10 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| MODIFIED FACTOR VII | 1995 |
|
RU2214833C2 |
| NEW TISSUE FACTOR ANTIBODIES AS ANTICOAGULANTS | 2003 |
|
RU2345789C2 |
| VASCULARISATION MODULATION TECHNIQUE | 2005 |
|
RU2378006C2 |
| DERIVATIVES OF FACTOR OF VII BLOOD COAGULATION | 2002 |
|
RU2338752C2 |
| NEW THROMBOMODULINE FUSION PROTEINS PROVIDING DIRECTIONAL TRANSFER TO TISSUE FACTOR AS ANTICOAGULANTS | 2003 |
|
RU2320366C2 |
| POLYPEPTYDE OF HEMOSTASIS FACTOR VII, PRODUCTION AND APPLICATION | 2001 |
|
RU2326126C2 |
| USE OF CHIGLITAZAR AND RELATED COMPOUNDS | 2019 |
|
RU2769446C1 |
| FACTOR VII CHIMERIC MOLECULES | 2010 |
|
RU2563231C2 |
| MODIFIED FACTOR VII-BASED POLYPEPTIDES AND THEREOF APPLICATION | 2008 |
|
RU2571931C2 |
| MODIFIED COAGULATION FACTOR VIIa WITH EXTENDED HALF-LIFE | 2007 |
|
RU2466141C2 |
